ARTICLE | Finance
Still some pop in Benlysta
March 14, 2011 7:00 AM UTC
Human Genome Sciences Inc. (NASDAQ:HGSI) gained $446 million in market cap last week on the approval of Benlysta belimumab, benefitting from a better label and pricing than investors had expected.
The approval was announced post-market on Wednesday. On Thursday, HGS gained $3.35 (13%) to $29.03. Sliding a bit on Friday, the shares finished up $2.36 to $27.94 on the week...